Perillyl alcohol modulates activation, permeability and integrity of human brain endothelial cells induced by Plasmodium falciparum.
Humans
Plasmodium falciparum
Intercellular Adhesion Molecule-1
/ metabolism
Endothelial Cells
Vascular Cell Adhesion Molecule-1
/ metabolism
Brain
/ metabolism
Malaria, Cerebral
/ metabolism
Malaria, Falciparum
Monoterpenes
/ metabolism
Blood-Brain Barrier
/ metabolism
Endothelium, Vascular
Permeability
Journal
Memorias do Instituto Oswaldo Cruz
ISSN: 1678-8060
Titre abrégé: Mem Inst Oswaldo Cruz
Pays: Brazil
ID NLM: 7502619
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
02
2023
accepted:
26
05
2023
medline:
6
7
2023
pubmed:
5
7
2023
entrez:
5
7
2023
Statut:
epublish
Résumé
Cerebral malaria (CM) is a severe immunovasculopathy caused for Plasmodium falciparum infection, which is characterised by the sequestration of parasitised red blood cells (pRBCs) in brain microvessels. Previous studies have shown that some terpenes, such as perillyl alcohol (POH), exhibit a marked efficacy in preventing cerebrovascular inflammation, breakdown of the brain-blood barrier (BBB) and brain leucocyte accumulation in experimental CM models. To analyse the effects of POH on the endothelium using human brain endothelial cell (HBEC) monolayers co-cultured with pRBCs. The loss of tight junction proteins (TJPs) and features of endothelial activation, such as ICAM-1 and VCAM-1 expression were evaluated by quantitative immunofluorescence. Microvesicle (MV) release by HBEC upon stimulation by P. falciparum was evaluated by flow cytometry. Finally, the capacity of POH to revert P. falciparum-induced HBEC monolayer permeability was examined by monitoring trans-endothelial electrical resistance (TEER). POH significantly prevented pRBCs-induced endothelial adhesion molecule (ICAM-1, VCAM-1) upregulation and MV release by HBEC, improved their trans-endothelial resistance, and restored their distribution of TJPs such as VE-cadherin, Occludin, and JAM-A. POH is a potent monoterpene that is efficient in preventing P. falciparum-pRBCs-induced changes in HBEC, namely their activation, increased permeability and alterations of integrity, all parameters of relevance to CM pathogenesis.
Sections du résumé
BACKGROUND
BACKGROUND
Cerebral malaria (CM) is a severe immunovasculopathy caused for Plasmodium falciparum infection, which is characterised by the sequestration of parasitised red blood cells (pRBCs) in brain microvessels. Previous studies have shown that some terpenes, such as perillyl alcohol (POH), exhibit a marked efficacy in preventing cerebrovascular inflammation, breakdown of the brain-blood barrier (BBB) and brain leucocyte accumulation in experimental CM models.
OBJECTIVE
OBJECTIVE
To analyse the effects of POH on the endothelium using human brain endothelial cell (HBEC) monolayers co-cultured with pRBCs.
METHODOLOGY
METHODS
The loss of tight junction proteins (TJPs) and features of endothelial activation, such as ICAM-1 and VCAM-1 expression were evaluated by quantitative immunofluorescence. Microvesicle (MV) release by HBEC upon stimulation by P. falciparum was evaluated by flow cytometry. Finally, the capacity of POH to revert P. falciparum-induced HBEC monolayer permeability was examined by monitoring trans-endothelial electrical resistance (TEER).
FINDINGS
RESULTS
POH significantly prevented pRBCs-induced endothelial adhesion molecule (ICAM-1, VCAM-1) upregulation and MV release by HBEC, improved their trans-endothelial resistance, and restored their distribution of TJPs such as VE-cadherin, Occludin, and JAM-A.
CONCLUSIONS
CONCLUSIONS
POH is a potent monoterpene that is efficient in preventing P. falciparum-pRBCs-induced changes in HBEC, namely their activation, increased permeability and alterations of integrity, all parameters of relevance to CM pathogenesis.
Identifiants
pubmed: 37403869
pii: S0074-02762023000101113
doi: 10.1590/0074-02760230033
pmc: PMC10317308
pii:
doi:
Substances chimiques
Intercellular Adhesion Molecule-1
126547-89-5
perillyl alcohol
319R5C7293
Vascular Cell Adhesion Molecule-1
0
Monoterpenes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e230033Références
Future Microbiol. 2012 Feb;7(2):291-302
pubmed: 22324996
Front Immunol. 2019 Jan 29;9:3100
pubmed: 30761156
Immunol Rev. 1989 Dec;112:49-70
pubmed: 2575074
Cell Cycle. 2014;13(9):1400-12
pubmed: 24626186
Malar J. 2007 May 16;6:59
pubmed: 17506896
Lancet. 1990 Nov 17;336(8725):1201-4
pubmed: 1978068
Virulence. 2012 Mar-Apr;3(2):193-201
pubmed: 22460644
Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):325-331
pubmed: 30339917
Science. 1976 Aug 20;193(4254):673-5
pubmed: 781840
Int J Antimicrob Agents. 2018 Mar;51(3):370-377
pubmed: 28843818
Parasitology. 1988 Jun;96 ( Pt 3):579-89
pubmed: 2457201
Microbes Infect. 2002 Mar;4(3):291-300
pubmed: 11909739
Front Immunol. 2018 Dec 19;9:3006
pubmed: 30619355
J Clin Invest. 1999 Jul;104(1):93-102
pubmed: 10393703
JAMA. 2007 May 23;297(20):2232-40
pubmed: 17519413
Front Immunol. 2019 Jul 24;10:1747
pubmed: 31396236
Blood Transfus. 2015 Apr;13(2):274-80
pubmed: 25369588
J Infect Dis. 2003 Feb 1;187(3):461-6
pubmed: 12552430
Neuropathol Appl Neurobiol. 1999 Aug;25(4):331-40
pubmed: 10476050
Sci Rep. 2019 Sep 20;9(1):13621
pubmed: 31541129
FASEB J. 2017 Jul;31(7):2817-2827
pubmed: 28314769
Glia. 2017 Jan;65(1):75-92
pubmed: 27696532
PLoS One. 2010 Oct 14;5(10):e13415
pubmed: 20976232
mBio. 2015 Sep 22;6(5):e01390-15
pubmed: 26396242
Prog Neurobiol. 2010 Jun;91(2):140-51
pubmed: 20117166
Am J Trop Med Hyg. 2001 Mar-Apr;64(3-4):207-13
pubmed: 11442219
Sci Rep. 2021 Jun 8;11(1):12077
pubmed: 34103601
Pediatr Infect Dis J. 2001 Sep;20(9):908-11
pubmed: 11734774
PLoS Pathog. 2014 Mar 20;10(3):e1003839
pubmed: 24651155
Neurology. 2000 Jul 12;55(1):104-11
pubmed: 10891914
J Neurosci. 2005 Aug 10;25(32):7352-8
pubmed: 16093385
J Exp Med. 1992 Oct 1;176(4):1183-9
pubmed: 1383378
Eur J Cell Biol. 2005 Jan;84(1):15-27
pubmed: 15724813
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3497-502
pubmed: 8622965
Clin Neuropathol. 1993 May-Jun;12(3):142-6
pubmed: 8100753
Int J Parasitol. 1999 Jun;29(6):927-37
pubmed: 10480730
Antimicrob Agents Chemother. 2021 Mar 1;65(5):
pubmed: 33649109
Trends Parasitol. 2006 Nov;22(11):503-8
pubmed: 16979941
Hum Immunol. 2013 Jun;74(6):713-21
pubmed: 23459075
J Infect Dis. 1999 Nov;180(5):1742-6
pubmed: 10515846